Annuncio pubblicitario
Italia markets closed
  • FTSE MIB

    33.922,16
    +40,66 (+0,12%)
     
  • Dow Jones

    37.868,56
    +93,18 (+0,25%)
     
  • Nasdaq

    15.253,36
    -348,14 (-2,23%)
     
  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     
  • Petrolio

    83,14
    +0,41 (+0,50%)
     
  • Bitcoin EUR

    60.286,68
    +920,62 (+1,55%)
     
  • CMC Crypto 200

    1.381,89
    +69,27 (+5,28%)
     
  • Oro

    2.410,80
    +12,80 (+0,53%)
     
  • EUR/USD

    1,0651
    +0,0005 (+0,04%)
     
  • S&P 500

    4.957,32
    -53,80 (-1,07%)
     
  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     
  • Euro Stoxx 50

    4.918,09
    -18,48 (-0,37%)
     
  • EUR/GBP

    0,8608
    +0,0052 (+0,61%)
     
  • EUR/CHF

    0,9692
    -0,0019 (-0,19%)
     
  • EUR/CAD

    1,4649
    -0,0002 (-0,01%)
     

6,214 Orion Corporation A shares converted into B shares

Orion Oyj
Orion Oyj

ORION CORPORATION
STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
28 JUNE 2022 at 9.30 EEST

6,214 Orion Corporation A shares converted into B shares

In accordance with Section 3 of the Articles of Association of Orion Corporation, 6,214 A shares have been converted into 6,214 B shares. The conversion has been entered into the Trade Register on 28 June 2022.

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,476,321 A shares and 106,657,957 B shares. The number of votes of the company's shares is after the conversion 796,184,377.

ANNUNCIO PUBBLICITARIO

Orion Corporation

Jari Karlson

CFO

   

Olli Huotari

SVP, Corporate Functions

 


Contact person:
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.